GlaxoSmithKline Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
GlaxoSmithKline Pharmaceuticals has a total shareholder equity of ₹15.4B and total debt of ₹213.8M, which brings its debt-to-equity ratio to 1.4%. Its total assets and total liabilities are ₹32.7B and ₹17.3B respectively. GlaxoSmithKline Pharmaceuticals's EBIT is ₹7.6B making its interest coverage ratio -11.2. It has cash and short-term investments of ₹16.1B.
Key information
1.4%
Debt to equity ratio
₹213.80m
Debt
Interest coverage ratio | -11.2x |
Cash | ₹16.05b |
Equity | ₹15.40b |
Total liabilities | ₹17.31b |
Total assets | ₹32.70b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 500660's short term assets (₹25.0B) exceed its short term liabilities (₹14.6B).
Long Term Liabilities: 500660's short term assets (₹25.0B) exceed its long term liabilities (₹2.7B).
Debt to Equity History and Analysis
Debt Level: 500660 has more cash than its total debt.
Reducing Debt: 500660's debt to equity ratio has increased from 0.03% to 1.4% over the past 5 years.
Debt Coverage: 500660's debt is well covered by operating cash flow (3222.5%).
Interest Coverage: 500660 earns more interest than it pays, so coverage of interest payments is not a concern.